A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04042558 |
|
Recruitment Status :
Recruiting
First Posted : August 2, 2019
Last Update Posted : August 1, 2023
|
Sponsor:
Centre Francois Baclesse
Collaborator:
GFPC
Information provided by (Responsible Party):
Centre Francois Baclesse
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Actual Primary Completion Date : | October 22, 2021 |
| Estimated Study Completion Date : | June 2024 |